The U.S. FDA has approved Lupin's Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet, as bioequivalent to Lokelma® for Oral Suspension, the reference listed drug (RLD) of AstraZeneca Pharmaceuticals LP. Sodium Zirconium Cyclosilicate for Oral Suspension, with Lokelma® as the reference listed drug, had estimated annual sales of USD 568 million in the United States, according to IQVIA MAT June 2026 data. The company's communication also includes a Safe Harbor Statement, noting that Lokelma® is a registered trademark of ZS Pharma, Inc. The approval represents Lupin's latest U.S. regulatory milestone for its Sodium Zirconium Cyclosilicate Oral Suspension in 5 g/packet and 10 g/packet strengths. The product has received U.S. FDA approval as bioequivalent to the reference listed drug Lokelma®, with an indication for treating hyperkalemia in adults.